Contents
Key findings
- 1Bremelanotide acts centrally on melanocortin receptors — a mechanism for desire, not blood flow — which is why it was developed for HSDD rather than as a PDE5-inhibitor alternative.
- 2In the RECONNECT phase 3 trials, improvements in desire and distress scores were statistically significant but modest; about 40% of women experienced nausea and about 18% discontinued for adverse events versus 2% on placebo.
- 3The label warns of transient blood-pressure increases after each dose and contraindicates use in uncontrolled hypertension or known cardiovascular disease.
- 4Studies in men with erectile dysfunction in the early 2000s showed erectile responses but the programme was halted; there is no approval for men.
- 5"PT-141" sold online is not Vyleesi; it is an unregulated product of unverified content.
Evidence level
Established for acquired, generalised HSDD in premenopausal women (two phase 3 RCTs, ~1,200 women, modest effect sizes). Preliminary at best for men and erectile dysfunction, based on early-2000s studies that did not lead to approval.
Regulatory status
FDA-approved June 2019 as bremelanotide (Vyleesi) for HSDD in premenopausal women; not approved for men, postmenopausal women or any other use. Products sold online as "PT-141" are not the approved drug.
PT-141 is unusual among peptides sold online: it actually became an approved drug. That is both the reason it has real evidence and the reason it is so often misrepresented — the approval is narrow, the effect is modest, and the population it is marketed to online is not the one it was approved for.
The question readers ask
Does PT-141 work, and for whom? For premenopausal women with acquired, generalised hypoactive sexual desire disorder, it produces small, statistically significant improvements in desire and distress at the cost of frequent nausea. For men, it was studied and abandoned; no approval exists.
What PT-141 is and how it works
PT-141 is the development code for bremelanotide, a cyclic seven-amino-acid peptide. It was first noticed as a metabolite of melanotan II, a synthetic tanning peptide, when trial participants reported spontaneous erections. Chemically it is a melanocortin-receptor agonist, acting on MC4R and other melanocortin receptors in the central nervous system that are involved in sexual desire and arousal.
That mechanism matters for expectations: PT-141 is not a "female Viagra". Sildenafil and its relatives increase genital blood flow; bremelanotide acts on brain pathways for desire. It was therefore developed for a desire disorder, not for arousal or erectile function.
The established evidence: HSDD in premenopausal women
Two identical phase 3 trials (RECONNECT) randomised 1,267 premenopausal women with acquired, generalised hypoactive sexual desire disorder to bremelanotide 1.75 mg by autoinjector, used as needed before sexual activity, or placebo, for 24 weeks[1]. Both trials met their co-primary endpoints: the desire domain of the Female Sexual Function Index rose more with bremelanotide than placebo, and a distress score fell more. The differences were statistically robust and clinically small — a few tenths of a point on the desire scale — and the number of satisfying sexual events, a key secondary endpoint, did not differ significantly.
Study details: Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
- Study type
- Two randomised, double-blind, placebo-controlled 24-week trials
- Population
- Premenopausal women with acquired, generalised HSDD
- Sample size
- 1267
- Primary result
- FSFI desire domain increased ~0.3–0.4 points more than placebo; distress decreased; effect sizes small; nausea ~40%.
- Limitations
- Subjective endpoints; sponsor-run; high adverse-event discontinuation.
- Year
- 2019
- Source
- Obstetrics & Gynecology(link not yet independently re-verified)
Adverse events were the story of the trials. About 40% of women on bremelanotide reported nausea (versus about 1% on placebo), and about 18% discontinued for adverse events versus 2% on placebo. Flushing, injection-site reactions and headache were common. Focal hyperpigmentation — darkening of the face, gums or breasts — occurred in about 1%, more with frequent use.
The FDA approved bremelanotide as Vyleesi in June 2019 for that indication[3]. The label limits use to one dose per 24 hours and no more than eight per month, warns of transient blood-pressure increases and heart-rate decreases after each dose, and contraindicates use in uncontrolled hypertension or known cardiovascular disease[4].
The abandoned evidence: men and erectile dysfunction
In the early 2000s, PT-141 (then intranasal, later subcutaneous) was studied in men with erectile dysfunction, including men who did not respond to sildenafil. Early-phase studies reported erectile responses along with nausea and blood-pressure effects[2]. The male programme was halted — blood-pressure concerns are usually cited — and no phase 3 trial or approval for men followed.
Online marketing of "PT-141 for men" rests on those older, small studies. It is not wrong to say PT-141 produced erectile responses in men in early trials. It is wrong to imply that it is an established, approved, or characterised treatment for men.
What has not been studied
- Postmenopausal women (excluded from the approval).
- Women without a diagnosed desire disorder ("libido enhancement").
- Long-term use beyond the trial durations.
- The unregulated products sold as "PT-141".
Regulatory position
FDA-approved as a prescription drug for one indication. Not approved for men, postmenopausal women, or any other use. Products sold online as "PT-141" are not the approved product; they are unregulated peptides of unverified identity and purity, carrying whatever the molecule's blood-pressure effects are plus whatever else is in the vial.
Grades by claim
| Claim | Best evidence | Grade |
|---|---|---|
| Improves desire in premenopausal women with HSDD | Two phase 3 RCTs, n=1,267 | Established evidenceApproved; modest effect |
| Treats erectile dysfunction in men | Early-phase studies, programme halted | Preliminary evidenceNot confirmed; not approved |
| Enhances libido in people without a disorder | None | Unsupported evidenceNot studied |
| Works in postmenopausal women | Limited | Preliminary evidenceNot studied adequately |
Where to go next
- PT-141 profile.
- Sexual health hub.
- FDA-approved, off-label, investigational and unapproved peptides.
Frequently asked questions
- How does PT-141 work?
- It activates melanocortin receptors in the brain involved in sexual desire and arousal. Unlike sildenafil-type drugs it does not primarily act on genital blood flow.
- Is PT-141 approved for men?
- No. Early studies in men with erectile dysfunction showed responses, but the programme was stopped, partly over blood-pressure effects, and no approval for men exists.
- How effective is Vyleesi?
- In phase 3 trials the improvements in desire and distress scores were statistically significant but modest, and about 40% of women had nausea.
- Is online PT-141 the same as Vyleesi?
- No. Vyleesi is a prescription autoinjector; "PT-141" sold online is an unregulated product whose content is unverified.
References
Numbered in order of first use. Study type is shown for every source; see our methodology for how we rank evidence.
- 1.
Kingsberg SA, Clayton AH, Portman D, et al.. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials Obstetrics & Gynecology, 2019.
Randomized controlled trialPremenopausal women with acquired, generalised HSDDn = 1267
Result: FSFI desire domain increased ~0.3–0.4 points more than placebo; distress decreased; effect sizes small; nausea ~40%.
Limitations: Subjective endpoints; sponsor-run; high adverse-event discontinuation.
↑ back to text - 2.
Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141 in healthy male subjects and in patients with an inadequate response to Viagra International Journal of Impotence Research, 2004.
Human studyHealthy men and men with ED unresponsive to sildenafil
Result: Erectile responses observed; nausea and blood-pressure effects noted.
Limitations: Early-phase; programme in men later halted.
↑ back to text - 3.
FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women U.S. Food and Drug Administration, 2019.
Regulatory source
Result: Approval; label warnings on blood pressure and hyperpigmentation.
↑ back to text - 4.
Vyleesi (bremelanotide) prescribing information (DailyMed search) U.S. National Library of Medicine, DailyMed.
Regulatory source
Result: Indication, contraindications, warnings, adverse reactions.
↑ back to text
Review status: Editorially reviewed against primary sources. This article was fact-checked against the primary sources listed in the references by our editorial team, and it has not been reviewed by a licensed clinician. It is educational content, not medical advice. Read our editorial policy and methodology. Spotted an error? Tell us.
